<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35322916</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1582-4934</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cellular and molecular medicine</Title>
          <ISOAbbreviation>J Cell Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways.</ArticleTitle>
        <Pagination>
          <StartPage>2673</StartPage>
          <EndPage>2685</EndPage>
          <MedlinePgn>2673-2685</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.17278</ELocationID>
        <Abstract>
          <AbstractText>TRIP13 is a member of the large superfamily of the AAA + ATPase proteins and is associated with a variety of activities. Emerging evidence has shown that TRIP13 may serve as an oncogene. However, the function of TRIP13 in breast cancer (BC) has not yet been elucidated. Here, a variety of bioinformatic tools and laboratory experiments were combined to analyse the expression patterns, prognostic value and functional network of TRIP13 in BC. Multiple databases and immunohistochemistry (IHC) indicated a higher TRIP13 expression in BC tissue compared with normal tissue. TRIP13 was highly expressed in lung metastatic lesions compared with primary tumours in a 4T1 cell implantation BALB/c mouse model of BC. Kaplan-Meier plots also revealed that high TRIP13 expression correlated with poor survival in patients with BC. Furthermore, gene set enrichment analysis revealed that TRIP13 was primarily enriched in the signalling pathway of PI3K-AKT-mTOR. Suppressing TRIP13 could inhibit the expression of related genes, as well as the proliferation and migration of BC cell. Finally, 10 hub genes with a high score of connectivity were filtered from the protein-protein interaction (PPI) network, including MAD2L1, CDC20, CDC5L, CDK1, CCNA2, BUB1B, RAD51, SPO11, KIF11 and AURKB. Thus, TRIP13 may be a promising prognostic biomarker and an effective therapeutic target for BC.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lan</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Jingzhan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tao</LastName>
            <ForeName>Xinyi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Longshan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Weiqiang</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Junjie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Chuqin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Yunyao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Lixin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiaolong</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-5899-6563</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Cell Mol Med</MedlineTA>
        <NlmUniqueID>101083777</NlmUniqueID>
        <ISSNLinking>1582-1838</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508357">CDC5L protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.4.-</RegistryNumber>
          <NameOfSubstance UI="D000074183">ATPases Associated with Diverse Cellular Activities</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.4.-</RegistryNumber>
          <NameOfSubstance UI="C575259">TRIP13 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000074183" MajorTopicYN="N">ATPases Associated with Diverse Cellular Activities</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">TRIP13</Keyword>
        <Keyword MajorTopicYN="Y">breast cancer</Keyword>
        <Keyword MajorTopicYN="Y">cell proliferation</Keyword>
        <Keyword MajorTopicYN="Y">prognosis</Keyword>
        <Keyword MajorTopicYN="Y">therapeutic target</Keyword>
      </KeywordList>
      <CoiStatement>All authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>8</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35322916</ArticleId>
        <ArticleId IdType="pmc">PMC9077308</ArticleId>
        <ArticleId IdType="doi">10.1111/jcmm.17278</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87‐108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25651787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005;365(9472):1727‐1741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15894099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fan L, Strasser‐Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279‐289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24872111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271‐3277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20498394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee JW, Choi HS, Gyuris J, Brent R, Moore DD. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol Endocrinol. 1995;9(2):243‐254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7776974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vader G. Pch2(TRIP13): controlling cell division through regulation of HORMA domains. Chromosoma. 2015;124(3):333‐339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25895724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dazhi W, Mengxi Z, Fufeng C, Meixing Y. Elevated expression of thyroid hormone receptor‐interacting protein 13 drives tumorigenesis and affects clinical outcome. Biomark Med. 2017;11(1):19‐31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27827544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yost S, de Wolf B, Hanks S, et al. Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation. Nat Genet. 2017;49(7):1148‐1151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5493194</ArticleId>
            <ArticleId IdType="pubmed">28553959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Banerjee R, Russo N, Liu M, et al. TRIP13 promotes error‐prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun. 2014;5:4527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4130352</ArticleId>
            <ArticleId IdType="pubmed">25078033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sheng N, Yan L, Wu K, et al. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer. Cell Death Dis. 2018;9(3):402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5852242</ArticleId>
            <ArticleId IdType="pubmed">29540729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang G, Zhu Q, Fu G, et al. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c‐MYC axis. Br J Cancer. 2019;121(12):1069‐1078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6964669</ArticleId>
            <ArticleId IdType="pubmed">31740732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data‐mining platform. Neoplasia. 2004;6(1):1‐6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1635162</ArticleId>
            <ArticleId IdType="pubmed">15068665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649‐658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5516091</ArticleId>
            <ArticleId IdType="pubmed">28732212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome‐wide validation of survival‐associated biomarkers in ovarian‐cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197‐208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22277193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi‐omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956‐D963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5753188</ArticleId>
            <ArticleId IdType="pubmed">29136207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258‐261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC165481</ArticleId>
            <ArticleId IdType="pubmed">12519996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(D1):D447‐D452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4383874</ArticleId>
            <ArticleId IdType="pubmed">25352553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ogura T, Wilkinson AJ. AAA+ superfamily ATPases: common structure–diverse function. Genes Cells. 2001;6(7):575‐597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11473577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miniowitz‐Shemtov S, Eytan E, Kaisari S, Sitry‐Shevah D, Hershko A. Mode of interaction of TRIP13 AAA‐ATPase with the Mad2‐binding protein p31comet and with mitotic checkpoint complexes. Proc Natl Acad Sci USA. 2015;112(37):11536‐11540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4577139</ArticleId>
            <ArticleId IdType="pubmed">26324890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Snider J, Houry WA. AAA+ proteins: diversity in function, similarity in structure. Biochem Soc Trans. 2008;36(Pt 1):72‐77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18208389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wendler P, Ciniawsky S, Kock M, Kube S. Structure and function of the AAA+ nucleotide binding pocket. Biochem Biophys Acta. 2012;1823(1):2‐14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21839118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Marks DH, Thomas R, Chin Y, Shah R, Khoo C, Benezra R. Mad2 overexpression uncovers a critical role for TRIP13 in mitotic exit. Cell Rep. 2017;19(9):1832‐1845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5526606</ArticleId>
            <ArticleId IdType="pubmed">28564602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ye Q, Rosenberg SC, Moeller A, Speir JA, Su TY, Corbett KD. TRIP13 is a protein‐remodeling AAA+ ATPase that catalyzes MAD2 conformation switching. eLife. 2015;4:e07367.</Citation>
        </Reference>
        <Reference>
          <Citation>
Tao Y, Yang G, Yang H, et al. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget. 2017;8(16):26718‐26731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5432292</ArticleId>
            <ArticleId IdType="pubmed">28157697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhu MX, Wei CY, Zhang PF, et al. Correction to: elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. J Exp Clin Cancer Res. 2019;38(1):443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6822571</ArticleId>
            <ArticleId IdType="pubmed">31666112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895‐904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16892035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591‐602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16056258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pulaski BA, Ostrand‐Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2000;39(1):Unit 20.22.</Citation>
        </Reference>
        <Reference>
          <Citation>
Shan D, Chen L, Njardarson JT, et al. Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice. Proc Natl Acad Sci USA. 2005;102(10):3772‐3776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC553334</ArticleId>
            <ArticleId IdType="pubmed">15728385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Park ES, Kim SJ, Kim SW, et al. Cross‐species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci USA. 2011;108(42):17456‐17461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3198333</ArticleId>
            <ArticleId IdType="pubmed">21987811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vanharanta S, Massagué J. Origins of metastatic traits. Cancer Cell. 2013;24(4):410‐421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3998120</ArticleId>
            <ArticleId IdType="pubmed">24135279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aghazadeh Y, Papadopoulos V. The role of the 14‐3‐3 protein family in health, disease, and drug development. Drug Discovery Today. 2016;21(2):278‐287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26456530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226(2):352‐364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21990031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kastan MB, Bartek J. Cell‐cycle checkpoints and cancer. Nature. 2004;432(7015):316‐323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15549093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274‐293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3331679</ArticleId>
            <ArticleId IdType="pubmed">22500797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21‐35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3390257</ArticleId>
            <ArticleId IdType="pubmed">21157483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Powell E, Piwnica‐Worms D, Piwnica‐Worms H. Contribution of p53 to metastasis. Cancer Discov. 2014;4(4):405‐414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4063123</ArticleId>
            <ArticleId IdType="pubmed">24658082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Murugan AK. mTOR: Role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019;59:92‐111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31408724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maes A, Menu E, Veirman K, Maes K, Vand Erkerken K, De Bruyne E. The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget. 2017;8(52):90501‐90520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685770</ArticleId>
            <ArticleId IdType="pubmed">29163849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Darling S, Fielding AB, Sabat‐Pospiech D, Prior IA, Coulson JM. Regulation of the cell cycle and centrosome biology by deubiquitylases. Biochem Soc Trans. 2017;45(5):1125‐1136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5652225</ArticleId>
            <ArticleId IdType="pubmed">28900014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Malumbres M, Barbacid M. Is Cyclin D1‐CDK4 kinase a bona fide cancer target?
Cancer Cell. 2006;9(1):2‐4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16413464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Herrera MC, Chymkowitch P, Robertson JM, et al. Cdk1 gates cell cycle‐dependent tRNA synthesis by regulating RNA polymerase III activity. Nucleic Acids Res. 2018;46(22):11698‐11711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6294503</ArticleId>
            <ArticleId IdType="pubmed">30247619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2(1):21‐32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11413462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. Transcription‐associated cyclin‐dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 2020;10(3):351‐370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32071145</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
